Description:

miR-21isoverexpressedinawidevarietyofcancers.Itisbelievedtobeanoncogenebydownregulatingtheexpressionofmanytumorsuppressors,includingprogrammedcelldeath4(PDCD4),tumorsuppressorPdcd4,thePTENtumorsuppressorgene,andthetumorsuppressorgenetropomyosin1(TPM1).miR-21isalsofoundtobeanimportantregulatorofcancer-cellsurvival.DifferentfromthesurvivalpathwaymediatedbyIL-6/Stat3activationthroughtheexpressionofantiapoptoticproteins,miR-21isupregulatedbyStat3,whichmediatesthesuppressionofapoptosispossIBLythroughtheinhibitionofTPM1and/orotherproteins. Signosis’miR-21plateassaykit providesasimpleandquick methodtoanalyzethismiRNAmolecule.

Principle:

IntheproprietarymiRNAplateassay,onemiRNAmoleculeisflankedbyacaptureoligoandabiotinateddetectionoligothroughtwobridgesoligos.OneofthebridgeoligosispartiallyhybridizedwiththemiRNAmoleculeandthecaptureoligoandanotherwiththemiRNAandthedetectionoligo.Thehybridisimmobilizedontoplatethroughhybridizationwithanimmobilizedoligoanddetectedbyastreptavidin-HRPconjugateandchemiluminecscentsubstrate.ThishybridstructureissensitivetothesequenceofthemiRNAmolecule.OnenucleotidedifferencewillpreventtheformationofthehybridandthereforemiRNAisoformcanbedifferentiated,whichnormallyishardtotacklewithNorthernblot.Inaddition,thesensitivityoftheassayishigherthanmiRNANorthernblotassay.

Data:

miRNAplateanalysisofmiR-21expression.A:expressionofmiR-21inhumanovary,kidney,andHeLawasanalyzedwithmiR-21Northernblot(top)andmiR-21plateassay(bottom).B:miR-21wasanalyzedwithdilutionsofHeLatotalRNA.

Signosis 是一家专业的生物分析供应商，致力于基于微孔板分析技术的生命科学研究产品的开发、生产和销售。Signosis 成立于2007年，坐落于世界研发中心--美国硅谷的中心地带。公司专注于细胞因子、转录因子、miRNA及疾病标志物等重要调控因子和标志物的研究，基于自有专利技术，开发完成400多种先进而独特的用于发现、筛选和分析的生命科学研究产品。Signosis 产品销售遍布北美、欧洲、亚洲及中东等主要国家和地区，客户涵盖美国国立卫生研究院、哈佛大学、耶鲁大学等著名研究机构以及众多制药公司